Did You Invest in UBS Yield Optimization Notes?

Soreide Law Group is investigating claims on behalf of UBS investors who have sustained losses investing in UBS Yield Optimization Notes. Yield Optimization Notes, otherwise known as reverse convertibles, are complex structured products with substantial risk. Reverse convertibles are the subject of multiple regulatory investigations. Upon information and belief, UBS did not require option suitability approval for Yield Optimization Note clients. UBS Yield Optimization Notes purchasers were buying the equivalent of a short put transaction. UBS marketed these products on certain volatile stocks that have suffered substantial declines including Micron, RIMM, US Steel, First Solar, and others including structured products such as UBS 100% principal protection notes, UBS Yield Optimization Notes with Contingent Protection, UBS Bullish Underlying Linked Securities (UBS BULS), and UBS Enhanced Appreciation Securities (UBS EAS).

UPDATE 9/29/2016

Soreide Law Group was among the first to discover these notes had negatively effected many investors.  There are several reverse convertible notes products that were sold to over 8,000 investors.  These were often unsuitable and not meant for unsophisticated investors.  Many investors suffered heavy losses that they were not able to recover and these losses were far beyond a market level loss.

UBS Yield Optimization Notes

Trigger Autocall Optimization Securities

Trigger Yield Optimization Notes

Trigger Phoenix Autocall Optimization Securities

Airbag Autocallable Yield Optimization Note

Airbag Yield Optimization Securities